1. Market Research
  2. > Okairos AG - Product Pipeline Review - 2013

Okairos AG - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

Okairos AG - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Okairos AG - Product Pipeline Review - 2013” provides data on the Okairos AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Okairos AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Okairos AG and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Okairos AG - Brief Okairos AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Okairos AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Okairos AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Okairos AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Okairos AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Okairos AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Okairos AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Okairos AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Okairos AG and identify potential opportunities in those areas.

Table Of Contents

Okairos AG - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Okairos AG Snapshot 5
Okairos AG Overview 5
Key Information 5
Key Facts 5
Okairos AG - Research and Development Overview 6
Key Therapeutic Areas 6
Okairos AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Okairos AG - Pipeline Products Glance 10
Okairos AG Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Okairos AG - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Okairos AG - Drug Profiles 13
Cancer Vaccine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Ebola And Marburg Vaccine Programme 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
HIV Vaccine Program 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Malaria Vaccine Programme 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ProCvax 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Respiratory Syncytial Virus Vaccine Programme 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
TerCvax 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Tuberculosis Vaccine Program 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Universal Influenza Vaccine Program 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Okairos AG - Pipeline Analysis 23
Okairos AG - Pipeline Products by Therapeutic Class 23
Okairos AG - Pipeline Products by Route of Administration 25
Okairos AG - Recent Pipeline Updates 26
Okairos AG - Dormant Projects 28
Okairos AG - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables


Okairos AG, Key Information 5
Okairos AG, Key Facts 5
Okairos AG - Pipeline by Indication, 2013 7
Okairos AG - Pipeline by Stage of Development, 2013 8
Okairos AG - Monotherapy Products in Pipeline, 2013 9
Okairos AG - Phase II, 2013 10
Okairos AG - Phase I, 2013 11
Okairos AG - Pre-Clinical, 2013 12
Okairos AG - Pipeline By Therapeutic Class, 2013 24
Okairos AG - Pipeline By Route of Administration, 2013 25
Okairos AG - Recent Pipeline Updates, 2013 26
Okairos AG - Dormant Developmental Projects,2013 28

List of Figures


Okairos AG - Pipeline by Indication, 2013 7
Okairos AG - Pipeline by Stage of Development, 2013 8
Okairos AG - Monotherapy Products in Pipeline, 2013 9
Okairos AG - Pipeline By Therapeutic Class, 2013 23
Okairos AG - Pipeline By Route of Administration, 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.